Varian Medical Systems Taiwan Co., Ltd.

At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. Our 11,000 employees across 70 locations keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

Veterans Affairs Council

Develop precision health care such as smart medicine and cell therapy

Vigorous Health Company Limited

Hydrogen Healthcare Products:
1000cc H2 Generator, 600cc 2-in-1 H2 Gas/Water Generator, 300cc H2 Generator, 150 cc H2 Generator, Enriched H2 Water Generator, H2 Capsule

Visionatics Inc.

Digital Magnetic Barcoded beads (DMB) fluorescence reader is a laboratory tool of great assistance for biomedical researchers. It is used for multiplex detection in immunoassays and molecular assays. In one experimental reaction, multiple pathogens can be detected at the same time. It has the advantages of rapid, accurate and high-throughput detection. A high throughput platform for viral detection will contribute to cope with mass test needs of clinical samples during the pandemic outbreak of highly infectious diseases such as Covid-19 and dengue fever. The technologies of barcoded beads multiplex detections also increase the sensibility of severe disease prediction, and help reduce public healthcare expenses.

VITAE Biomedical Co. Ltd.

According to statistics published by WHO, lung cancer was the leading cause of cancer deaths in 2020, accounting for close to 1.8 million death cases worldwide. Muted symptoms in its early stages make lung cancer screening especially challenging. Indeed, early detection is quintessential to pivot the ongoing situation. As of today, health practitioners globally have been conducting chest X-rays and/or LDCT scans for lung cancer screening. While chest X-ray screening proves the lack of substantial benefit for lung cancer survival rate, LDCT, on the contrary, tends to lead to over diagnosis. Both methods require intensive experience for cancer diagnosis in addition to real concerns over exposures to radiation. The VITAE Biomedical lung cancer IVD reagent kit helps detect a specific biomarker in patients’ urine for lung cancer screening. This breakthrough service is non-invasive, non-radiative, and made possible for early detection. It provides excellent benefit-to-risk ratio for the public and is expected to be the go-to screening technology for high-risk individuals and lung cancer patients who can benefit from continuous monitoring anytime and anywhere.

Vitae Biomedical Co. Ltd.

Lung cancer was the leading cause of cancer deaths, accounting for 1.8 million death cases worldwide in 2020. Prolonged asymptomatic period in early stages make screening especially challenging. Indeed, early detection is quintessential to pivot this situation.
Today, health practitioners globally have been conducting chest X-rays and LDCT scans for lung cancers. While chest X-ray screening proves the lack of substantial benefit for survival rate, LDCT, on the contrary, tends to lead to over diagnosis. Both methods require intensive experience for cancer diagnosis in addition to real concerns over exposures to radiation. Vitae Biomedical lung cancer IVD reagent kit helps detect a highly specific biomarker in urine for lung cancers. This breakthrough technology is non-invasive, non-radiative, and proved possible for early detection. It provides excellent benefit-to-risk ratio and is the go-to screening technology for any individual and lung cancer patients who can benefit from continuous monitoring anytime and anywhere.

VOLER Biotech Consulting Co., Ltd.

VOLER Biotech Consulting Co., Ltd. was established in 2017.It is composed of a group of Taiwan biotechnology industry experts. We assists Taiwan biotechnology industry in consulting services such as medical device, medicine and regulations.